https://regulatorynews.com/abbott-cardiomems-dynamic-treatment-plan-app Regulatory News en 2026-10-13T10:52:40-04:00 FDA Clears Patient App for Abbott's CardioMEMS Monitor https://regulatorynews.com/novartis-rhapsido-dermographism-approval Regulatory News en 2026-10-13T09:52:51-04:00 Novartis Earns FDA Nod for First Dermographism Drug https://regulatorynews.com/icotec-cmore-ct-cms-reimbursement Regulatory News en 2026-10-13T09:41:50-04:00 icotec Wins Medicare Add-On Payment for CMORE CT https://regulatorynews.com/retension-pharmaceuticals-ipo-financing Regulatory News en 2026-10-13T09:41:50-04:00 Retension Pharmaceuticals Prices $45M Nasdaq IPO https://regulatorynews.com/abbvie-temab-a-breakthrough-designations Regulatory News en 2026-10-13T06:06:20-04:00 AbbVie's Temab-A Wins Two FDA Breakthrough Tags https://regulatorynews.com/okami-lobo-venous-indication-expansion Regulatory News en 2026-10-13T06:06:20-04:00 FDA Expands Okami's LOBO Occluder to Veins https://regulatorynews.com/tucatinib-her2-breast-cancer-maintenance-practice-impact Regulatory News en 2026-10-12T10:50:20-04:00 FDA Adds Tucatinib to HER2+ Breast Cancer Maintenance https://regulatorynews.com/heartbeam-breakthrough-device-designation Regulatory News en 2026-10-12T09:36:47-04:00 HeartBeam Wins FDA Breakthrough Status for Heart Attacks https://regulatorynews.com/matchpoint-therapeutics-series-b-financing Regulatory News en 2026-10-12T09:36:47-04:00 Matchpoint Raises $150M to Push a Covalent Drug to Clinic https://regulatorynews.com/zydus-lifesciences-riociguat-generic-launch Regulatory News en 2026-10-12T09:36:47-04:00 Zydus Launches First Generic Adempas Rival in the US https://regulatorynews.com/natera-mced-breakthrough-device-designation Regulatory News en 2026-10-12T06:06:06-04:00 FDA Grants Breakthrough Status to Natera Cancer Test https://regulatorynews.com/urolution-openflo-catheter-510k-clearance Regulatory News en 2026-10-12T06:06:06-04:00 FDA Clears Urolution OpenFlo Urinary Catheter https://regulatorynews.com/teva-weltruza-olanzapine-schizophrenia-approval Regulatory News en 2026-10-12T05:58:42-04:00 FDA Approves Teva's Weltruza for Schizophrenia